This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management

Authoring team

Treatment depends upon the age of the patient, the clinical presentation, and the nature of the tumour. Options are medical, surgical or radiotherapy.

Medical treatments:

  • somatostatin analogues - inhibit growth hormone production. Also, may be effective against TSH adenomas.
  • bromocriptine and cabergoline - these are dopamine agonists that lowers circulating hormone levels. Especially for prolactinomas.

Surgical approaches:

  • trans-sphenoidal
  • trans-ethmoidal
  • transfrontal - for tumours with large frontal or lateral extensions. Necessitates a craniotomy flap.

Radiotherapy:

  • pituitary adenomas are radiosensitive. External irradation is most often employed. Less commonly, radioactive seeds of gold are implanted into the pituitary fossa. Hormone levels fall after several months. Replacement hormone therapy is necessary in the long term (5-10 years) due to decline in pituitary function.

As a guide, large tumours usually require surgical decompression followed by radiotherapy and correction of underlying endocrine abnormalities with steroid cover prior to surgery. For small tumours treat the underlying hormonal disturbance.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.